LIVIVO - Search results -

Search results

Result 1 - 10 of total 39

Search options

Article ; Online: Diagnostic performance and impact on patient management of [68Ga]Ga-DOTA-TOC PET/CT in colorectal neuroendocrine tumors derived from hindgut.

Delabie, Pierre / Baudin, Éric / Hentic, Olivia / Afchain, Pauline / Rusu, Timofei / Montravers, Françoise

2022 Volume 101, Issue 47, Page(s) e31512

Abstract: The main purpose of this retrospective study was to determine the diagnostic performance of [68Ga]Ga-DOTA-D-Phe1-Try3-octreotide(DOTA-TOC) positron emission tomography/computed tomography (PET/CT) in patients with well-differentiated colorectal ... ...

Abstract	The main purpose of this retrospective study was to determine the diagnostic performance of [68Ga]Ga-DOTA-D-Phe1-Try3-octreotide(DOTA-TOC) positron emission tomography/computed tomography (PET/CT) in patients with well-differentiated colorectal Neuroendocrine Tumours (NETs) originating from the hindgut. The other aims were to assess the impact of the examination on patient management and to analyze the results of 2-[18F]FDG and/or 6-[18F]FDOPA PET/CT when they were performed. [68Ga]Ga-DOTA-TOC PET/CT and clinical data from 30 patients with biopsy-proven well-differentiated NETs originating from the hindgut were retrospectively reviewed and analyzed by comparing the [68Ga]Ga-DOTA-TOC PET/CT findings with pathological and/or follow-up data. We also compared the [68Ga]Ga-DOTA-TOC PET/CT results with 2-[18F]FDG and/or 6-[18F]FDOPA PET/CT results in 6 patients. The impact on management was determined in hindsight by comparing the patient management decided before and after the TEP examination based on data from multidisciplinary team meetings. On a patient basis, [68Ga]Ga-DOTA-TOC PET/CT was accurate in 30 of the 30 examinations. [68Ga]Ga-DOTA-TOC PET/CT correctly identified the primary tumor in all patients with primary tumors not resected before the examination and allowed the detection of unexpected distant metastases in 36% of the patients referred for initial staging. [68Ga]Ga-DOTA-TOC PET/CT findings affected patient management in 57% of cases with generally major intermodality changes. Intraindividual comparison of the results of the different PET radiopharmaceuticals showed a clear superiority of [68Ga]Ga-DOTA-TOC PET/CT considering both the number of lesions and the intensity of uptake. [68Ga]Ga-DOTA-TOC PET/CT is an accurate imaging modality for the assessment of well-differentiated colorectal NETs that highly impact patient management. Thus, we suggest that [68Ga]Ga-DOTA-TOC PET/CT be employed as a first choice for the assessment of these tumors in nuclear medicine.
MeSH term(s)	Humans ; Positron Emission Tomography Computed Tomography ; Neuroendocrine Tumors/diagnostic imaging ; Retrospective Studies ; Fluorodeoxyglucose F18 ; Colorectal Neoplasms/diagnostic imaging
Chemical Substances	Fluorodeoxyglucose F18 (0Z5B2CJX4D) ; 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid (1HTE449DGZ)
Language	English
Publishing date	2022-12-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	80184-7
ISSN	1536-5964 ; 0025-7974
ISSN (online)	1536-5964
ISSN	0025-7974
DOI	10.1097/MD.0000000000031512
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.171: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by

Al Mansour, Laure / De Mestier, Louis / Haissaguerre, Magalie / Afchain, Pauline / Hadoux, Julien / Lecomte, Thierry / Morland, David / Cottereau, Anne Segolene / De Rycke, Ophelie / Tlili, Ghoufrane / Tordo, Jérémie / Janier, Marc / Deville, Agathe / Walter, Thomas

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

2024 Volume 65, Issue 2, Page(s) 258–263

Abstract: A mesenteric mass (MM), characterized by fibrotic reaction, is present in most small-intestinal neuroendocrine tumors (SI-NETs). ...

Abstract	A mesenteric mass (MM), characterized by fibrotic reaction, is present in most small-intestinal neuroendocrine tumors (SI-NETs).
MeSH term(s)	Humans ; Neuroendocrine Tumors/metabolism ; Treatment Outcome ; Octreotide/adverse effects ; Endocrine Gland Neoplasms ; Intestinal Neoplasms/radiotherapy ; Intestinal Neoplasms/drug therapy ; Radioisotopes/therapeutic use ; Receptors, Peptide/metabolism ; Organometallic Compounds/adverse effects ; Radionuclide Imaging ; Positron-Emission Tomography
Chemical Substances	copper dotatate CU-64 ; Octreotide (RWM8CCW8GP) ; Radioisotopes ; Receptors, Peptide ; Organometallic Compounds
Language	English
Publishing date	2024-02-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	80272-4
ISSN	1535-5667 ; 0097-9058 ; 0161-5505 ; 0022-3123
ISSN (online)	1535-5667
ISSN	0097-9058 ; 0161-5505 ; 0022-3123
DOI	10.2967/jnumed.123.266063
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 114: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 328: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The Need for Centralization for Small Intestinal Neuroendocrine Tumor Surgery: A Cohort Study from the GTE-Endocan-RENATEN Network, the CentralChirSINET Study.

Kalifi, Maroin / Deguelte, Sophie / Faron, Matthieu / Afchain, Pauline / de Mestier, Louis / Lecomte, Thierry / Pasquer, Arnaud / Subtil, Fabien / Alghamdi, Khalid / Poncet, Gilles / Walter, Thomas

Annals of surgical oncology

2023 Volume 30, Issue 13, Page(s) 8528–8541

Abstract: Background: The concept of surgical centralization is becoming more and more accepted for specific surgical procedures.: Objective: The aim of this study was to evaluate the relationship between procedure volume and the outcomes of surgical small ... ...

Abstract	Background: The concept of surgical centralization is becoming more and more accepted for specific surgical procedures. Objective: The aim of this study was to evaluate the relationship between procedure volume and the outcomes of surgical small intestine (SI) neuroendocrine tumor (NET) resections. Methods: We conducted a retrospective national study that included patients who underwent SI-NET resection between 2019 and 2021. A high-volume center (hvC) was defined as a center that performed more than five SI-NET resections per year. The quality of the surgical resections was evaluated between hvCs and low-volume centers (lvCs) by comparing the number of resected lymph nodes (LNs) as the primary endpoint. Results: A total of 157 patients underwent surgery in 33 centers: 90 patients in four hvCs and 67 patients in 29 lvCs. Laparotomy was more often performed in hvCs (85.6% vs. 59.7%; p < 0.001), as was right hemicolectomy (64.4% vs. 38.8%; p < 0.001), whereas limited ileocolic resection was performed in 18% of patients in lvCs versus none in hvCs. A bi-digital palpation of the entire SI length (95.6% vs. 34.3%, p < 0.001), a cholecystectomy (93.3% vs. 14.9%; p < 0.001), and a mesenteric mass resection (70% vs. 35.8%; p < 0.001) were more often performed in hvCs. The proportion of patients with ≥8 LNs resected was significantly higher (96.3% vs. 65.1%; p < 0.001) in hvCs compared with lvCs, as was the proportion of patients with ≥12 LNs resected (87.8% vs. 52.4%). Furthermore, the number of patients with multiple SI-NETs was higher in the hvC group compared with the lvC group (43.3% vs. 25.4%), as were the number of tumors in those patients (median of 7 vs. 2; p < 0.001). Conclusions: Optimal SI-NET resection was significantly more often performed in hvCs. Centralization of surgical care of SI-NETs is recommended.
MeSH term(s)	Humans ; Cohort Studies ; Retrospective Studies ; Neuroendocrine Tumors ; Hospitals, High-Volume ; Hospitals, Low-Volume
Language	English
Publishing date	2023-10-09
Publishing country	United States
Document type	Journal Article
ZDB-ID	1200469-8
ISSN	1534-4681 ; 1068-9265
ISSN (online)	1534-4681
ISSN	1068-9265
DOI	10.1245/s10434-023-14276-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4042: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Use of Proton Pump Inhibitors and Risk of Pancreatic Cancer: A Nationwide Case-Control Study Based on the French National Health Data System (SNDS).

Lassalle, Marion / Le Tri, Thien / Afchain, Pauline / Camus, Marine / Kirchgesner, Julien / Zureik, Mahmoud / Dray-Spira, Rosemary

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

2021 Volume 31, Issue 3, Page(s) 662–669

Abstract: Background: Only a few studies investigated the association between proton pump inhibitor (PPI) use and pancreatic cancer, with inconsistent results. Moreover, these studies had a number of methodologic limitations. Our objective was to assess this ... ...

Abstract	Background: Only a few studies investigated the association between proton pump inhibitor (PPI) use and pancreatic cancer, with inconsistent results. Moreover, these studies had a number of methodologic limitations. Our objective was to assess this association in a nationwide case-control study. Methods: We used the French National Health Data System (SNDS), covering 99% of the French population since 2006. Incident cases of pancreatic cancer, identified between 2014 and 2018, were matched with up to four controls on year of birth, sex, frequency of hospitalization within 8 years prior to index date, and department of residence. Associations between PPIs and pancreatic cancer were estimated using conditional logistic regression models adjusted for sociodemographic characteristics, risk factors of pancreatic cancer (including diabetes mellitus, tobacco-related diseases, and morbid obesity), and other comorbidities. Results: A total of 23,321 cases of pancreatic cancer (mean age, 69.8 years; 51.7% males) and 75,937 matched controls were included. Overall, 77.8% of cases and 75.5% of controls were PPI ever users. Ever (vs. never) PPI use was associated with an increased risk of pancreatic cancer [adjusted OR (aOR) = 1.05, 95% confidence interval (CI), 1.01-1.09]. A dose-response relationship was observed [1-30 cumulative defined daily dose (cDDD): aOR = 0.92, 95% CI, 0.87-0.97; 31-180 cDDD: aOR = 1.05, 95% CI, 1.00-1.11; 181-1,080 cDDD: aOR = 1.18, 95% CI, 1.12-1.24; >1,080 cDDD: aOR = 1.17, 95% CI, 1.10-1.23]. Conclusions: On the basis of these findings, a slight increase in the risk of pancreatic cancer associated with high cumulative doses of PPIs cannot be excluded. Impact: Given the overuse of PPIs, efforts should be continued to limit treatments to appropriate indications and durations.
MeSH term(s)	Aged ; Case-Control Studies ; Female ; Humans ; Male ; Pancreatic Neoplasms/chemically induced ; Pancreatic Neoplasms/epidemiology ; Proton Pump Inhibitors/adverse effects ; Risk Factors ; Pancreatic Neoplasms
Chemical Substances	Proton Pump Inhibitors
Language	English
Publishing date	2021-12-13
Publishing country	United States
Document type	Journal Article
ZDB-ID	1153420-5
ISSN	1538-7755 ; 1055-9965
ISSN (online)	1538-7755
ISSN	1055-9965
DOI	10.1158/1055-9965.EPI-21-0786
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3693: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Nouvelles classifications moléculaires du cancer colorectal, du cancer du pancréas et du cancer de l'estomac : vers un traitement à la carte ?

Dreyer, Chantal / Afchain, Pauline / Trouilloud, Isabelle / André, Thierry

Bulletin du cancer

2016 Volume 103, Issue 7-8, Page(s) 643–650

Abstract: This review reports 3 of recently published molecular classifications of the 3 main gastro-intestinal cancers: gastric, pancreatic and colorectal adenocarcinoma. In colorectal adenocarcinoma, 6 independent classifications were combined to finally hold 4 ... ...

Title translation	New molecular classification of colorectal cancer, pancreatic cancer and stomach cancer: Towards "à la carte" treatment?.
Abstract	This review reports 3 of recently published molecular classifications of the 3 main gastro-intestinal cancers: gastric, pancreatic and colorectal adenocarcinoma. In colorectal adenocarcinoma, 6 independent classifications were combined to finally hold 4 molecular sub-groups, Consensus Molecular Subtypes (CMS 1-4), linked to various clinical, molecular and survival data. CMS1 (14% MSI with immune activation); CMS2 (37%: canonical with epithelial differentiation and activation of the WNT/MYC pathway); CMS3 (13% metabolic with epithelial differentiation and RAS mutation); CMS4 (23%: mesenchymal with activation of TGFβ pathway and angiogenesis with stromal invasion). In gastric adenocarcinoma, 4 groups were established: subtype "EBV" (9%, high frequency of PIK3CA mutations, hypermetylation and amplification of JAK2, PD-L1 and PD-L2), subtype "MSI" (22%, high rate of mutation), subtype "genomically stable tumor" (20%, diffuse histology type and mutations of RAS and genes encoding integrins and adhesion proteins including CDH1) and subtype "tumors with chromosomal instability" (50%, intestinal type, aneuploidy and receptor tyrosine kinase amplification). In pancreatic adenocarcinomas, a classification in four sub-groups has been proposed, stable subtype (20%, aneuploidy), locally rearranged subtype (30%, focal event on one or two chromosoms), scattered subtype (36%,<200 structural variation events), and unstable subtype (14%,>200 structural variation events, defects in DNA maintenance). Although currently away from the care of patients, these classifications open the way to "à la carte" treatment depending on molecular biology.
MeSH term(s)	Adenocarcinoma/classification ; Adenocarcinoma/genetics ; Adenocarcinoma/mortality ; B7-H1 Antigen/genetics ; B7-H1 Antigen/metabolism ; Cell Adhesion Molecules/genetics ; Cell Adhesion Molecules/metabolism ; Class I Phosphatidylinositol 3-Kinases ; Colorectal Neoplasms/classification ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/mortality ; Genes, myc ; Genes, ras ; Humans ; Janus Kinase 2/genetics ; Janus Kinase 2/metabolism ; Mutation ; Pancreatic Neoplasms/classification ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/mortality ; Phosphatidylinositol 3-Kinases/genetics ; Programmed Cell Death 1 Ligand 2 Protein/genetics ; Programmed Cell Death 1 Ligand 2 Protein/metabolism ; Stomach Neoplasms/classification ; Stomach Neoplasms/genetics ; Stomach Neoplasms/mortality ; Transcriptional Activation ; Transforming Growth Factor beta/genetics ; Transforming Growth Factor beta/metabolism ; Wnt Proteins/genetics ; Wnt Proteins/metabolism
Chemical Substances	B7-H1 Antigen ; Cell Adhesion Molecules ; PDCD1LG2 protein, human ; Programmed Cell Death 1 Ligand 2 Protein ; Transforming Growth Factor beta ; Wnt Proteins ; Phosphatidylinositol 3-Kinases (EC 2.7.1.-) ; Class I Phosphatidylinositol 3-Kinases (EC 2.7.1.137) ; PIK3CA protein, human (EC 2.7.1.137) ; JAK2 protein, human (EC 2.7.10.2) ; Janus Kinase 2 (EC 2.7.10.2)
Language	French
Publishing date	2016-07
Publishing country	France
Document type	Journal Article ; Review
ZDB-ID	213270-9
ISSN	1769-6917 ; 0007-4551
ISSN (online)	1769-6917
ISSN	0007-4551
DOI	10.1016/j.bulcan.2016.05.007
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.15: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: ERBB3

Cabel, Luc / Aparicio, Thomas / Bieche, Ivan / Svrcek, Magali / Zaanan, Aziz / Afchain, Pauline / Di Fiore, Frédéric / Gornet, Jean-Marc / Le Corre, Delphine / Vacher, Sophie / Callens, Celine / Bernard, Virginie / Laurent-Puig, Pierre / Bidard, François-Clément

JCO precision oncology

2022 Volume 2, Page(s) 1–9

Abstract: Purpose: Functional studies have demonstrated that some mutations of : Materials and methods: DNA from 74 SBAs, previously characterized for : Results: Four of 74 SBAs (5.4%) displayed : Conclusion: SBAs display a high rate ... ...

Abstract	Purpose: Functional studies have demonstrated that some mutations of Materials and methods: DNA from 74 SBAs, previously characterized for Results: Four of 74 SBAs (5.4%) displayed Conclusion: SBAs display a high rate of
Language	English
Publishing date	2022-01-27
Publishing country	United States
Document type	Journal Article
ISSN	2473-4284
ISSN (online)	2473-4284
DOI	10.1200/PO.17.00243
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study.

JNCI cancer spectrum

2023 Volume 7, Issue 5

Abstract: Background: Small bowel adenocarcinoma is a rare cancer, and the role of adjuvant chemotherapy for localized disease is still debated.: Methods: This retrospective multicenter study included all consecutive patients who underwent curative surgical ... ...

Abstract	Background: Small bowel adenocarcinoma is a rare cancer, and the role of adjuvant chemotherapy for localized disease is still debated. Methods: This retrospective multicenter study included all consecutive patients who underwent curative surgical resection for localized small bowel adenocarcinoma between 1996 and 2019 from 3 French cohort studies. Prognostic and predictive factors of adjuvant chemotherapy efficacy were analyzed for disease-free survival and overall survival. The inverse probability of treatment weighting method was applied in the Cox regression model using the propensity score derived from multivariable logistic regression. Results: A total of 354 patients were included: median age, 63.5 years; duodenum location, 53.5%; and tumor stage I, II, and III in 31 (8.7%), 144 (40.7%), and 179 (50.6%) patients, respectively. The adjuvant chemotherapy was administered in 0 (0%), 66 (48.5%), and 143 (80.3%) patients with stage I, II, and III, respectively (P < .0001). In the subgroup analysis by inverse probability of treatment weighting method, a statistically significant disease-free survival and overall survival benefit in favor of adjuvant chemotherapy was observed in high-risk stage II (T4 and/or <8 lymph nodes examined) and III (T4 and/or N2) but not for low-risk stage II (T3 and ≥8 lymph nodes examined) and III (T1-3/N1) tumors (Pinteraction < .05). Furthermore, tumor location in jejunum and ileum was also a statistically significant predictive factor of response to adjuvant chemotherapy in stage II and III tumors (Pinteraction < .05). Conclusion: In localized small bowel adenocarcinoma, adjuvant chemotherapy seems to provide a statistically significant survival benefit for high-risk stage II and III tumors and for jejunum and ileum tumor locations.
MeSH term(s)	Humans ; Middle Aged ; Adenocarcinoma/drug therapy ; Adenocarcinoma/surgery ; Adenocarcinoma/pathology ; Chemotherapy, Adjuvant ; Intestine, Small/pathology ; Intestine, Small/surgery ; Neoplasm Staging ; Prognosis ; Retrospective Studies
Language	English
Publishing date	2023-09-29
Publishing country	England
Document type	Multicenter Study ; Journal Article
ISSN	2515-5091
ISSN (online)	2515-5091
DOI	10.1093/jncics/pkad064
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.

Hadoux, Julien / Afchain, Pauline / Walter, Thomas / Tougeron, David / Hautefeuille, Vincent / Monterymard, Carole / Lorgis, Véronique / Thuillier, Frédéric / Baudin, Eric / Scoazec, Jean Yves / Lepage, Côme / Desgrippes, Romain

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

2021 Volume 53, Issue 7, Page(s) 824–829

Abstract: Background: Poorly differentiated neuroendocrine carcinomas (NEC) are rare diseases with a poor prognosis. Platinum-etoposide (PE) has been the recommended first-line treatment for decades. FOLFIRINEC (NCT04325425) is a national multicenter randomized ... ...

Abstract	Background: Poorly differentiated neuroendocrine carcinomas (NEC) are rare diseases with a poor prognosis. Platinum-etoposide (PE) has been the recommended first-line treatment for decades. FOLFIRINEC (NCT04325425) is a national multicenter randomized phase II study which aims to challenge this standard regimen. Methods: The primary objective is to compare the median progression-free survival (PFS) under mFOLFIRINOX versus PE. The secondary objectives are to evaluate the objective response rates (ORR), median overall survival (OS), safety and quality of life. The associated real-time translational study will establish a molecular profile for each patient enrolled. Main inclusion criteria are: NEC of gastroenteropancreatic (GEP) or unknown origin, metastatic and RECIST 1.1 evaluable disease, tumor sample available and no contraindication to chemotherapy. Patients will be randomized 1:1 between PE every 21 days for 6-8 cycles and mFOLFIRINOX every 14 days for up to 12 cycles and stratified according to center, performance status, Ki67 and pathological subtype. This trial will randomize 218 patients (24 months of follow-up) to have 80% power to detect an improvement of the median PFS from 5 months under PE to 7.5 months under mFOLFIRINOX (HR of 0.67, α =5%, two-sided). An intermediate analysis is planned at 50% of events. Recruitment started on October 20, 2020.
MeSH term(s)	Adult ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Biomarkers/analysis ; Carcinoma, Neuroendocrine/drug therapy ; Etoposide/administration & dosage ; Female ; Fluorouracil/administration & dosage ; Humans ; Intestinal Neoplasms/drug therapy ; Irinotecan/administration & dosage ; Leucovorin/administration & dosage ; Male ; Neoplasm Metastasis ; Neoplasms, Unknown Primary/drug therapy ; Neuroendocrine Tumors/drug therapy ; Oxaliplatin/administration & dosage ; Pancreatic Neoplasms/drug therapy ; Platinum Compounds/administration & dosage ; Progression-Free Survival ; Prospective Studies ; Quality of Life ; Stomach Neoplasms/drug therapy ; Survival Rate ; Treatment Outcome
Chemical Substances	Biomarkers ; Platinum Compounds ; folfirinox ; Oxaliplatin (04ZR38536J) ; Etoposide (6PLQ3CP4P3) ; Irinotecan (7673326042) ; Leucovorin (Q573I9DVLP) ; Fluorouracil (U3P01618RT)
Language	English
Publishing date	2021-05-12
Publishing country	Netherlands
Document type	Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Randomized Controlled Trial
ZDB-ID	1459373-7
ISSN	1878-3562 ; 1125-8055
ISSN (online)	1878-3562
ISSN	1125-8055
DOI	10.1016/j.dld.2021.04.016
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1134: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Small Bowel Adenocarcinoma.

Aparicio, Thomas / Zaanan, Aziz / Mary, Florence / Afchain, Pauline / Manfredi, Sylvain / Evans, Thomas Ronald Jeffry

Gastroenterology clinics of North America

2016 Volume 45, Issue 3, Page(s) 447–457

Abstract: Small bowel adenocarcinomas (SBAs) are rare tumors, but their incidence is increasing. The most common primary location is the duodenum. Even though SBAs are more often sporadic, some diseases are risk factors. Early diagnosis of small bowel ... ...

Abstract	Small bowel adenocarcinomas (SBAs) are rare tumors, but their incidence is increasing. The most common primary location is the duodenum. Even though SBAs are more often sporadic, some diseases are risk factors. Early diagnosis of small bowel adenocarcinoma remains difficult, despite significant radiologic and endoscopic progress. After R0 surgical resection, the main prognostic factor is lymph node invasion. An international randomized trial (BALLAD [Benefit of Adjuvant Chemotherapy For Small Bowel Adenocarcinoma] study) will evaluate the benefit of adjuvant chemotherapy. For metastatic disease, retrospectives studies suggest that platinum-based chemotherapy is the most effective treatment. Phase II studies are ongoing to evaluate targeted therapy in metastatic SBA.
MeSH term(s)	Adenocarcinoma/diagnosis ; Adenocarcinoma/genetics ; Adenocarcinoma/metabolism ; Adenocarcinoma/therapy ; Adenomatous Polyposis Coli Protein/genetics ; Capsule Endoscopy ; Chemotherapy, Adjuvant ; Digestive System Surgical Procedures ; Double-Balloon Enteroscopy ; Duodenal Neoplasms/diagnosis ; Duodenal Neoplasms/genetics ; Duodenal Neoplasms/metabolism ; Duodenal Neoplasms/therapy ; Humans ; Intestinal Neoplasms/diagnosis ; Intestinal Neoplasms/genetics ; Intestinal Neoplasms/metabolism ; Intestinal Neoplasms/therapy ; Intestine, Small ; Mutation ; Phenotype ; Prognosis ; Proto-Oncogene Proteins p21(ras)/genetics ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/metabolism ; Risk Factors ; Tomography, X-Ray Computed ; Tumor Suppressor Protein p53/metabolism ; beta Catenin/metabolism
Chemical Substances	APC protein, human ; Adenomatous Polyposis Coli Protein ; KRAS protein, human ; TP53 protein, human ; Tumor Suppressor Protein p53 ; beta Catenin ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1) ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2)
Language	English
Publishing date	2016-08-22
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	92114-2
ISSN	1558-1942 ; 0889-8553
ISSN (online)	1558-1942
ISSN	0889-8553
DOI	10.1016/j.gtc.2016.04.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Se 123: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Prise en charge thérapeutique des tumeurs neuroendocrines peu différenciées pulmonaires et des carcinomes neuroendocrines digestifs.

Pellat, Anna / Wislez, Marie / Svrcek, Magali / Hammel, Pascal / Afchain, Pauline / André, Thierry

Bulletin du cancer

2016 Volume 103, Issue 10, Page(s) 880–895

Abstract: Poorly differentiated neuroendocrine tumors are rare but their incidence is rising. High-grade neuroendocrine lung tumors, including small-cell lung cancer, are part of this group. Outside of the lung, they most often arise within the gastrointestinal ... ...

Title translation	Therapeutic management of poorly differentiated neuroendocrine lung tumors and neuroendocrine carcinomas of the digestive system.
Abstract	Poorly differentiated neuroendocrine tumors are rare but their incidence is rising. High-grade neuroendocrine lung tumors, including small-cell lung cancer, are part of this group. Outside of the lung, they most often arise within the gastrointestinal tract (oesophagus, guts and pancreas) and are called neuroendocrine carcinomas. Due to their rarity, very little is known about neuroendocrine carcinomas of the pancreas and the gastrointestinal tract and few studies have been done. Therefore, most therapeutic recommendations are issued from studies on small-cell lung cancers. Histological scores have grown more accurate these past few years: poorly differentiated neuroendocrine tumors regroup various entities such as small-cells, large-cells and mix tumors, which seem to have different prognosis. They are diagnosed at a metastatic state in more than 50 % of cases. In localised disease, surgery is performed on selected patients. Adjuvant chemotherapy is administered in poorly differentiated neuroendocrine tumors of the lung and is an option in neuroendocrine carcinomas, without proof of efficacy. If not operable, radiochemotherapy is done for tumors of the lung, rectum, and eosophagus. If the disease is diagnosed at a metastatic state, chemotherapy is administered with a combination of platin salts (cisplatin or carboplatin) and etoposide. In poorly differentiated neuroendocrine tumors of the lung, prophylactic cranial irradiation is performed in localized disease if there is a good response to chemotherapy. Even if these therapies have improved the overall survival, no improvement has been made during the past four decades and the prognosis remains low.
MeSH term(s)	Antineoplastic Agents ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Brain Neoplasms/prevention & control ; Brain Neoplasms/secondary ; Carcinoma, Neuroendocrine/pathology ; Carcinoma, Neuroendocrine/therapy ; Chemoradiotherapy/methods ; Combined Modality Therapy/methods ; Cranial Irradiation ; Digestive System Neoplasms/pathology ; Digestive System Neoplasms/therapy ; Humans ; Lung Neoplasms/pathology ; Lung Neoplasms/therapy ; Prognosis ; Rare Diseases/pathology ; Rare Diseases/therapy ; Small Cell Lung Carcinoma/pathology ; Small Cell Lung Carcinoma/therapy
Chemical Substances	Antineoplastic Agents
Language	French
Publishing date	2016-10
Publishing country	France
Document type	Journal Article
ZDB-ID	213270-9
ISSN	1769-6917 ; 0007-4551
ISSN (online)	1769-6917
ISSN	0007-4551
DOI	10.1016/j.bulcan.2016.06.006
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.15: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito